Breakthrough cancer pain:: Prevalence and characteristics in patients in Catalonia, Spain

被引:109
作者
Gómez-Batiste, X
Madrid, F
Moreno, F
Gracia, A
Trelis, J
Nabal, M
Alcalde, R
Planas, J
Camell, H
机构
[1] Inst Catala Oncol, Serv Cures Palliat, Barcelona 08907, Spain
[2] Grp Ferrer, Dept Med, Barcelona, Spain
[3] Hosp Univ Arnau de Vilanova, Lleida, Spain
[4] Hosp Santa Caterina, Girona, Spain
[5] Hosp Esperana, Barcelona, Spain
[6] Hosp Residencia Sant Camil, Barcelona, Spain
关键词
D O I
10.1016/S0885-3924(02)00421-9
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Breakthrough pain (BTP), a transitory exacerbation of pain superimposed on a background of persistent, usually adequately controlled pain, has been reported to occur in 50 % to 75 % of cancer patients. However, a 23 % prevalence of BTP was recently reported in a study of Spanish patients with advanced cancers, showing probably a low detection rate of this clinical problem. The purpose of the present study was to determine the prevalence of BTP among oncology patients managed by palliative care teams in Catalonia, Spain, and to characterize the frequency, intensity, and treatment of BTP episodes. Sixty-two teams studied. 397 patients on a predetermined, index day. BTP was reported by 163 (41 %) patients, with a total of 244 episodes (mean 1.5 episodes/patient/day). Mean (SD) intensity of BTP episodes was 7.3 (2.0), compared with 2.9 (2.7) for persistent pain (both 0-10 scales). Morphine was used to treat 52 % of BTP episodes, while 25 % were untreated. These findings indicate that BTP remains underrecognized and undertreated in Spain.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 11 条
  • [1] [Anonymous], 1994, AHCPR PUBLICATION
  • [2] CARULLA J, 1999, MED PALIATIVA, V6, P67
  • [3] Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
    Christie, JM
    Simmonds, M
    Patt, R
    Coluzzi, P
    Busch, MA
    Nordbrock, E
    Portenoy, RK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3238 - 3245
  • [4] Characterization of breakthrough pain by hospice patients and their caregivers
    Fine, PG
    Busch, MA
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (03) : 179 - 183
  • [5] PREDICTIVE FACTORS IN ADVANCED CANCER PAIN TREATED ONLY BY ANALGESICS
    MERCADANTE, S
    MADDALONI, S
    ROCCELLA, S
    SALVAGGIO, L
    [J]. PAIN, 1992, 50 (02) : 151 - 155
  • [6] Patt RB, 1998, ONCOLOGY-NY, V12, P1035
  • [7] Temporal presentation of chronic cancer pain: Transitory pains on admission to a multidisciplinary pain clinic
    Petzke, F
    Radbruch, L
    Zech, D
    Loick, G
    Grond, S
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 17 (06) : 391 - 401
  • [8] BREAKTHROUGH PAIN - DEFINITION, PREVALENCE AND CHARACTERISTICS
    PORTENOY, RK
    HAGEN, NA
    [J]. PAIN, 1990, 41 (03) : 273 - 281
  • [9] Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study
    Portenoy, RK
    Payne, R
    Coluzzi, P
    Raschko, JW
    Lyss, A
    Busch, MA
    Frigerio, V
    Ingham, J
    Loseth, DB
    Nordbrock, E
    Rhiner, M
    [J]. PAIN, 1999, 79 (2-3) : 303 - 312
  • [10] Breakthrough pain: characteristics and impact in patients with cancer pain
    Portenoy, RK
    Payne, D
    Jacobsen, P
    [J]. PAIN, 1999, 81 (1-2) : 129 - 134